Interleukin-17 in inflammatory skin disorders

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 5, 2007, Pages 374-381

  Van Beelen, Astrid J ^a   Teunissen, Marcel B M ^a   Kapsenberg, Martien L ^a   De Jong, Esther C ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atopic dermatitis; Contact hypersensitivity; Interleukin 17; Interleukin 17 producing CD4+ T helper cells; Psoriasis; Skin

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ACANTHOSIS; ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; BACTERIAL VIRULENCE; CANDIDA ALBICANS; CONTACT ALLERGY; CRYPTOCOCCUS NEOFORMANS; GRANULOCYTE; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; KLEBSIELLA PNEUMONIAE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN INFLAMMATION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-17; PSORIASIS; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 34548661488     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282ef869e     Document Type: Review

References (72)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
2. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20:561-567.
3. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002; 168:1704-1709.
4. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004; 16:21-25.
5. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4(+) effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132.
6. Park H, Li ZX, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-1141.
7. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-240.
8. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-1914.
9. Yao ZB, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811-821.
10. Yao ZB, Spriggs MK, Derry JMJ, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997; 9:794-800.
11. + T helper cells and that it is required for the presence of Th17 cells.
12. + T helper cells in mice.
13. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441:231-234. This paper shows that TGFβ acts to upregulate IL-23R expression and that IL-23 is required for host protection against Citrobacter rodentium.
14. Bettelli E, Carrier YJ, Gao WD, et al. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 2006; 441:235-238.
15. Kidoya H, Umemura M, Kawabe T, et al. Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production. J Immunol 2005; 175:8024-8031.
16. Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-1691. This paper shows that EAE is less severe in IL-1RI-deficient mice and that IL-23-induced IL-17 production was substantially enhanced by IL-1α or IL-1β.
17. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204:995-1001.
18. Schnyder-Candrian S, Togbe D, Couillin I, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203:2715-2725. This paper shows that IL-17 may be protective in models of asthma, as its administration in the chronic phase reduces eosinophilia and bronchial hyperreactivity.
19. Shibata K, Yamada H, Hara H, et al. Resident V delta 1(+) gamma delta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 2007; 178:4466-4472.
20. Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007; 178:3786-3796.
21. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gamma delta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177:4662-4669.
22. Stark MA, Huo YQ, Burcin TL, et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17 [abstract]. FASEB J 2004; 18:A827.
23. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-476.
24. Teunissen MBM, Koomen CW, Malefyt RD, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645-649.
25. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 162:494-502.
26. Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 2005; 202:761-769.
27. Malley R, Srivastava A, Lipsitch M, et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 2006; 74:2187-2195. This paper shows that treatment of mice with the antibody to IL-17A at the time of challenge reduces the immunity against Streptococcus pneumoniae.
28. Zwijnenburg PJG, van der Poll T, Florquin S, et al. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J Immunol 2003; 170:4724-4730.
29. Miller LS, O'Connell RM, Gutierrez MA, et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006; 24:79-91. This paper shows that IL-1R-deficient mice have reduced protection against Staphylococcus aureus.
30. Hohl TM, Rivera A, Pamer EG. Immunity to fungi. Curr Opin Immunol 2006; 18:465-472.
31. Leibundgut-Landmann S, Groß O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8:630-638. This paper shows that dectin-1 signaling, which is associated with yeast binding, primes dendritic cells to promote the development of IL-17-producing T cells.
32. Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 2006; 176:1098-1106. This paper shows that IL-23 is more important than IL-12 in protection against Cryptococcus neoformans.
33. Huang WT, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-631.
34. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162:1246-1251.
35. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-970.
36. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-1352.
37. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500-508.
38. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Multiple Sclerosis 1999; 5:101-104.
39. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463. This paper reports on the significant association between Crohn's disease and the IL-23R gene on chromosome 1p31.
40. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65-70.
41. + T cells inefficiently induced EAE in recipient mice.
42. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006; 12:382-388. This paper describes that IL-17R knockout mice were significantly protected against TNBS-induced colitis.
43. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951-1957.
44. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173-6177.
45. + T cells that selectively produce IL-17 and express transcription factor RORC. An important role for Th17 in the protection against fungal pathogens is suggested.
46. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400:776-780.
47. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164:6621-6632.
48. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005; 152:1098-1107.
49. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176:1908-1915. This paper demonstrates the enhanced expression of IL-23 in lesional psoriatic skin, being produced by keratinocytes, Langerhans cells, DDCs and macrophages.
50. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271-2279. This paper describes for the first time that IL-22 was coexpressed in vitro and in vivo with both IL-17A and IL-17F and that these cytokines synergistically induced the expression of antimicrobial peptides in keratinocytes.
51. •], this paper shows that IL-22 and IL-17 are coexpressed, but are differentially regulated by Th17 cells. IL-22 appears to be critical in IL-23-induced acanthosis and dermal inflammation in a mouse model.
52. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203:2577-2587.
53. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123:1037-1044.
54. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580-592. This extensive, double-blind, placebo-controlled trial convincingly demonstrates the clinical improvement of psoriasis patients after treatment with an IL-12/23p40 monoclonal antibody.
55. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177:4917-4926.
56. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19:37-44.
57. Albanesi C, Scarponi CS, Cavani A, et al. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000; 115:81-87.
58. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17:375-387.
59. Xu H, Banerjee A, Dilulio NA, Fairchild RL. Development of effector CD8(+) T cells in contact hypersensitivity occurs independently of CD4(+) T cells. J Immunol 1997; 158:4721-4728.
60. + T-cell-derived IL-17 rather than IFN-γ suppresses the elicitation of CHS.
61. Grewe M, Bruijnzeel-Koomen CAFM, Schopf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19:359-361.
62. Kawaguchi M, Onuchic LF, Li XD, et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol 2001; 167:4430-4435.
63. Bullens DMA, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res (in press).
64. Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108:430-438.
65. Toda M, Leung DYM, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111:875-881.
66. Hijnen DJ, Bruin-Weller M, Oosting B, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113:334-340.
67. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107:535-541.
68. Nakatani T, Kaburagi Y, Shimada Y, et al. CCR4(+) memory CD4(+) T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107:353-358.
69. Wakugawa M, Nakamura K, Kakinuma T, et al. CC chemokine receptor 4 expression on peripheral blood CD4(+) T cells reflects disease activity of atopic dermatitis. J Invest Dermatol 2001; 117:188-196.
70. Keller M, Spanou Z, Schaerli P, et al. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005; 175:7678-7686.
71. Ong PY, Leung DYM. The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and is decreased in atopic dermatitis as compared with psoriasis. J Invest Dermatol 2002; 119:1463-1464.
72. Schmuth M, Neyer S, Rainer C, et al. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002; 11:135-142.